These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24361757)

  • 1. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Rosenzweig M; Lane DA; Lip GY
    Am J Med; 2014 Apr; 127(4):329-336.e4. PubMed ID: 24361757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J; Giroud M; de Pouvourville G
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
    Ezekowitz MD; Wallentin L; Connolly SJ; Parekh A; Chernick MR; Pogue J; Aikens TH; Yang S; Reilly PA; Lip GY; Yusuf S;
    Circulation; 2010 Nov; 122(22):2246-53. PubMed ID: 21147728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial ischemic events in 'real world' patients treated with dabigatran.
    Shah R
    Am J Med; 2014 Oct; 127(10):e19. PubMed ID: 25311071
    [No Abstract]   [Full Text] [Related]  

  • 13. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
    Shurrab M; Morillo CA; Schulman S; Kansal N; Danon A; Newman D; Lashevsky I; Healey JS; Crystal E
    Can J Cardiol; 2013 Oct; 29(10):1203-10. PubMed ID: 23993352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
    Monz BU; Connolly SJ; Korhonen M; Noack H; Pooley J
    Int J Cardiol; 2013 Oct; 168(3):2540-7. PubMed ID: 23664436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.